Fig. 2: Chronology of emerging relapse evidence and survival graphs. | Blood Cancer Journal

Fig. 2: Chronology of emerging relapse evidence and survival graphs.

From: Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation

Fig. 2

A Swimmer plot of the 15 patients with relapse evidence and their outcomes, including 6 relapsed and 9 unrelapsed patients. The values of donor chimerism and JAK2-MRD VAF are presented in Supplementary Fig. 2. B Probability of overt relapse, relapse-free survival, and overall survival by JAK2-MRD ratio ≥3-fold at day +100. C Donor chimerism ≤77% at day +180, and D Donor chimerism ≤95% at day +180. Red positive, black negative. R-pt relapsed patient, UR-Pt unrelapsed patient, D day, MRD measurable residual disease, MC mixed chimerism, IST immunosuppressive therapy, VAF variant allele frequency, HCT hematopoietic stem cell transplantation, CI confidential interval, NA not available, MRD measurable residual disease, CIR cumulative incidence of relapse, RFS relapse-free survival, OS overall survival.

Back to article page